YD Bio Limited Warrants (YDESW) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$0.37

From 52W high−86.67%

Volume11758.00

Market cap$1.23M

P/E (TTM)—

P/S (TTM)2.1x

Div yield—

Key dataSep 18, 2026

Open

$0.37

From 52W high

−86.67%

Volume

11758.00

Market cap

$1.23M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−0.2x

P/E (TTM)

—

RSI (14)

48.8

MomentumView details →

1D Return

−0.72%

YTD Return

−63.64%

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−0.2x

EV/Sales

2.0x

P/S (TTM)

2.1x

P/B (TTM)

−0.1x

ProfitabilityView details →

Gross Margin

−7.06%

Net Margin

−1392.61%

EBITDA Margin

−1357.75%

ROE (TTM)

51.78%

ROA (TTM)

−281.60%

Asset Turnover

0.18x

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

+30.56%

EPS CAGR 3Y

+78.57%

EBITDA YoY

—

MomentumView details →

1D Return

−0.72%

YTD Return

−63.64%

1Y Return

−86.26%

RSI (14)

48.8

vs 50D SMA

+13.09%

vs 200D SMA

−41.26%

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

0.02x

Quick Ratio

0.02x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−2.97M

Op. CF (TTM)

−1.18M

Latest newsMore news →

YD Bio Limited announced its unaudited financial results for the six months ended June 30, 2026.20d ago

YD Bio, YD Bio US, EG BioMed US, and Numia Health launched a six-month pilot collaboration to evaluate a cross-border clinical workflow for physician-ordered, blood-based cancer testing for patients in British Columbia, Canada.54d ago

Similar companies

NeuroSense Therapeutics Ltd.NRSNW Liminatus Pharma, Inc. WarrantsLIMNW Abpro CorporationABP Scinai Immunotherapeutics Ltd.SCNI Iterum Therapeutics plcITRM Propanc Biopharma, Inc.PPCB Find similar companies →

Latest newsMore news →

YD Bio Limited announced its unaudited financial results for the six months ended June 30, 2026.20d ago YD Bio, YD Bio US, EG BioMed US, and Numia Health launched a six-month pilot collaboration to evaluate a cross-border clinical workflow for physician-ordered, blood-based cancer testing for patients in British Columbia, Canada.54d ago YD Bio's affiliate EG BioMed US obtained out-of-state clinical laboratory licenses in Rhode Island and Pennsylvania, expanding its U.S. laboratory footprint to 46 states for DNA-methylation early cancer detection operations.80d ago